Zeta BCL-2 Antibody. Zeta’s recombinant rabbit antibody recognizes BCL-2 (B Cell Lymphoma 2), a protoncogene mainly localized to inner mitochondrial membrane, endoplasmic reticulum and nuclear envelope. BCL-2 encodes a 25 kDa protein. BCL-2 prevents cells from undergoing apoptosis and may participate in ion channel formation and alteration of membrane permeability, necessary for initiation of apoptosis. Non-phosphorylated BCL-2 inhibits apoptosis, and Bax homodimers normally cause apoptosisB where Bax can bind to and inhibit non-phosphorylated BCL-2, promoting apoptosis. BCL-2 overexpression in osteoblasts causes osteocyte apoptosis. BCL-2 overexpression increase lifespan of B cells and may maintain memory B cells, plasma cells and neurons by prolonging life span without cell division.
BCL-2 can distinguish follicular hyperplasia of lymph node from follicular lymphoma. BCL-2 is usually overexpressed in follicular lymphoma, which brings BCL-2 gene adjacent to active immunoglobulin heavy chain gene. Follicular lymphomas are BCL-2 negative. BCL-2 can detect immature enteric ganglion cells in pediatric intestinal pseudo-obstruction. BCL-2 may have prognostic value in early stage breast cancer.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.